IMAX CORP
StoneX kept a Buy rating on Imax with a $65 price target, suggesting a 28.5% upside from its Oct 6 close. The firm cited Imax's strong 2027 content pipeline and record 3Q26 box office performance of $712 million as key drivers. According to StoneX, these factors support earnings growth and high margins.
Analysts reiterated Buy ratings on CoreWeave (CRWV) with a $153.00 target, IMAX (IMAX) with a $63.00 target, and Micron (MU) with a $1900.00 target. CRWV and MU have consensus Strong Buy ratings, while IMAX has a Moderate Buy. Price targets imply upsides of 61.7%, -5.3%, and 40.6% respectively.
AMC Entertainment (AMC) fell 7% after a 13% rally the prior session, with the stock still up 98% year to date. Cinemark (CNK) and IMAX (IMAX) dipped only 1-2%, suggesting AMC-specific selling. AMC's drop may be profit-taking after a sharp run, while broader theater sector remains stable.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning IMAX (IMAX CORP). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent IMAX coverage spans financial news, market movers and technology.
In the last 30 days, IMAX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.2M). The most active reporter was LISTER ROBERT D, Chief Legal Officer Sr Exec VP, with 1 filing.
Analyst upgrade with a higher price target may attract buying interest.
Steady Buy rating with modest downside target may keep the stock stable or slightly pressured.
IMAX may see slight short‑term weakness but no major catalyst.
The price rise reflects a delayed market reaction to the prior earnings beat; no new catalyst is present.
AMC Entertainment (AMC) rose 13% to $3.32, extending a rally after announcing a $3.97 billion refinancing package. Cinemark (CNK) and IMAX (IMAX) also gained, up 2% and 0.5% respectively. AMC's refinancing aims to reshape its debt load, pushing maturities further out, but final borrowing costs remain undisclosed.
AlphAI scores every news story that mentions IMAX with an AI model for sentiment and relevance, and aggregates insider trades from IMAX CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
StoneX kept a Buy rating on Imax with a $65 price target, suggesting a 28.5% upside from its Oct 6 close. The firm cited Imax's strong 2027 content pipeline and record 3Q26 box office performance of $712 million as key drivers. According to StoneX, these factors support earnings growth and high margins.
1 min readAnalysts reiterated Buy ratings on CoreWeave (CRWV) with a $153.00 target, IMAX (IMAX) with a $63.00 target, and Micron (MU) with a $1900.00 target. CRWV and MU have consensus Strong Buy ratings, while IMAX has a Moderate Buy. Price targets imply upsides of 61.7%, -5.3%, and 40.6% respectively.
2 min readAMC Entertainment (AMC) fell 7% after a 13% rally the prior session, with the stock still up 98% year to date. Cinemark (CNK) and IMAX (IMAX) dipped only 1-2%, suggesting AMC-specific selling. AMC's drop may be profit-taking after a sharp run, while broader theater sector remains stable.
2 min readIMAX (NYSE:IMAX) stock rose 67.2% to $41.11 after Q2 earnings. Getty Images (NYSE:GETY) reported a 2.5% revenue decline, missing estimates, and its stock fell 68.5% to $0.14. RUM Group (NASDAQ:RUM) saw a 60.9% revenue increase, beating expectations, and its stock rose 34.9% to $8.38. WEBTOON (NASDAQ:WBTN) reported a 2.8% revenue decline, missing estimates, and its stock rose 15.6% to $10.93.
2 min readAMC Entertainment (AMC) rose 13% to $3.32, extending a rally after announcing a $3.97 billion refinancing package. Cinemark (CNK) and IMAX (IMAX) also gained, up 2% and 0.5% respectively. AMC's refinancing aims to reshape its debt load, pushing maturities further out, but final borrowing costs remain undisclosed.
2 min readMorgan Stanley initiated coverage of Imax with an overweight rating and a $63 price target, suggesting 18% upside. The bank cites Imax's growing network, film slate, and box office revenue growth. Imax's box office is projected to reach $1.7 billion in 2028, up from $1.5 billion in 2026. The success of 'The Odyssey' highlights the value of Imax's technology and brand. 12 of 14 analysts rate Imax a buy or strong buy, and shares are up 21% over the past three months.
2 min readAnalysts made several rating changes and price target adjustments. JPMorgan upgraded CoreWeave, Welltower, and Macerich, while Citi downgraded Dropbox. Bernstein upgraded Quanta Services, and Morgan Stanley initiated Imax and Nvidia with overweight ratings. Other notable moves include upgrades for Arcturus Therapeutics, Dollar General, and The Brink's Company, and initiations for NeOnc Technologies, Energy Services of America, BayCom, Avidbank, and SpaceX.
3 min readMeta announced VR Glasses for Spring 2027 at $1,299.99, featuring 5K micro OLED, 100g weight, and IMAX streaming. The device uses an external processing puck for power and storage, with 3-hour battery life. No Malaysia pricing or release details yet.
2 min readMeta introduced lightweight VR glasses with 5K displays, IMAX support, and Disney+ integration. The glasses weigh significantly less than Quest 3, use micro-OLED displays, and are powered by Qualcomm's Snapdragon Reality Elite processor. Priced at $1,299.99, they launch in spring 2025. Meta aims to make VR more accessible and immersive.
2 min readIMAX Melbourne is the only cinema in the Southern Hemisphere to screen Christopher Nolan's THE ODYSSEY on IMAX 70mm Film. The theatre sold 17,000 tickets and $800,000 in box office revenue in under 24 hours. IMAX Melbourne is one of IMAX Corp's top 8 performing cinemas globally, with THE ODYSSEY expected to drive further demand.
1 min read
